If you take an expensive brand-name drug, either one you pick up at the pharmacy or one a clinic gives you by infusion or injection, Medicare just started testing a new way of deciding what it pays for it. The idea is to tie Medicare's payment to prices in other wealthy countries instead of letting the U.S. price stand alone.
The honest version is more complicated than either the coverage promising big savings or the criticism warning it will backfire. A study published in The Lancet this September modeled both the possible savings and the possible side effects, and it's worth separating what's confirmed from what's still a projection before you change anything.
Decision
Name how you get the drug you're tracking
Pick the one that matches, since the two pricing tracks work differently.
What "Most Favored Nation" Pricing Actually Changes
The policy runs as two separate models. GUARD applies to drugs bought at the pharmacy counter. GLOBE applies to drugs a provider administers directly, like an infusion or an injection given in a clinic. Both tie Medicare's payment to a reference price drawn from other high-income countries rather than the price a manufacturer sets for the U.S. market alone.
The Lancet study modeled 195 patented medicines covering $87.9 billion in Medicare spending, and only a random quarter of beneficiaries are covered in this first phase, which runs over roughly five years before any wider expansion is decided. If you haven't heard from your plan or provider about this directly, that's expected, not a sign you're being left out of something you need.
This is a separate program from Medicare's existing drug price negotiation authority, which already set lower prices for a different list of high-cost drugs. Read CMS May Make Medicare Drug Price Negotiation Rules Permanent if you want the older program's own timeline.
The Catch Worth Understanding Before You Read the Headlines
The same study is also the source of the warning headlines about global prices rising. Researchers found that for about three in four of the medicines they studied, the Medicare savings would be worth nearly four times that drug's annual profit in the country used to set the reference price, giving manufacturers a real incentive to raise prices abroad or delay launching new drugs there instead of losing that much U.S. revenue.
The study also found that confidential side agreements already announced with the first 17 manufacturers would cut the projected Medicare savings by about 71%. That doesn't mean the program fails, it means the eventual effect on U.S. drug costs is still unsettled, not a number you can bank on from this year's coverage.
Know what to ask before you call Medicare or Social Security.
Build my listClose tool
Prepare short, specific Medicare or Social Security questions before your next call.
Checklist
Confirm these two things before you assume you're affected
A quick question beats guessing from a headline.
0 of 2 done.
Checklist
Ask your pharmacist this at your next pickup
GUARD applies here, if it applies at all.
0 of 2 done.
Checklist
Separate the rule from the rumor
These are the two different claims circulating about this policy.
0 of 3 done.
Checklist
Bring these details to the call
Specifics get you a real answer faster than a general question.
0 of 3 done.
Timeline
Track this without overreacting to it
Check each step off as you go.
Confirm the exact name and dosage of the medication you're tracking.
Ask your pharmacist or billing office whether it falls under GUARD or GLOBE.
Use Medicare Open Enrollment to check your current drug list against next year's plan options.
CMS and plans notify affected beneficiaries directly, so a letter matters more than a headline.
Save what you tracked here so you have it ready for your next call.
Questions to Ask Before Your Next Refill or Infusion
Bring the drug's exact name, not just the condition it treats, since pricing programs apply to specific medications rather than entire categories. If you get it by infusion or injection, bring the billing code or procedure name from your last visit summary as well.
Write the answers down somewhere you'll actually find them again, ideally next to your plan's member services number, so you're not starting from zero at your next appointment.
Where the Official Numbers Will Show Up
CMS will publish the actual list of covered medicines and the notification process for beneficiaries as the program moves forward. Until that's public, treat any specific dollar figure you see as a model's estimate, not a bill you'll actually receive.
None of this changes what you should do during Medicare Open Enrollment. Read Medicare Open Enrollment 2027: What to Gather Now, Six Weeks Out and compare plans on your actual current drug list, not on a pricing pilot that hasn't reached most people yet.
Common questions
What is Medicare's "Most Favored Nation" drug pricing policy?
It's a pair of pilot programs, GUARD for pharmacy drugs and GLOBE for drugs a provider administers directly, that tie what Medicare pays for certain brand-name medicines to prices in other high-income countries. A random quarter of beneficiaries are covered in the first phase, which runs roughly five years before any wider expansion is decided.
Will this lower what I pay out of pocket for my prescriptions?
Not automatically. The pricing models change what Medicare pays the manufacturer, not necessarily your copay or coinsurance. Ask your pharmacist or plan directly whether your specific drug is included before assuming either a savings or no change at all.
Could this make my medication more expensive overseas or harder to get?
A Lancet study modeling the policy found that manufacturers have a financial incentive to raise prices abroad or delay launches outside the U.S. to protect revenue, but that's a projection based on how companies might respond, not a confirmed outcome. Confidential side deals with some manufacturers are already reducing the study's original savings estimates.
